Plasmodium falciparummalaria vaccines in development
- 1 March 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 7 (2) , 223-240
- https://doi.org/10.1586/14760584.7.2.223
Abstract
The development and implementation of a malaria vaccine would constitute a major breakthrough for global health. Recently, numerous new candidates have entered clinical testing, following strategies that are as diverse as the malaria cycle is complex. While promising results have been obtained, some candidate vaccines have not fulfilled expectations. The challenges are not merely scientific; further progresses will require the development of competent investigator networks, partnerships between academics, industry and funding agencies, and continuous political commitment. In this review, we present the developmental status of all malaria vaccine candidates that are currently in human clinical testing against Plasmodium falciparum, as well as selected malaria vaccine candidates at preclinical development stage, and discuss the main challenges facing the field of malaria vaccine development.Keywords
This publication has 142 references indexed in Scilit:
- Malaria and HIV: a silent allianceTrends in Parasitology, 2007
- Structural basis of antigenic escape of a malaria vaccine candidateProceedings of the National Academy of Sciences, 2007
- Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity toPlasmodium falciparumCS Compared to That with Either Malaria Vaccine AloneInfection and Immunity, 2007
- A genome-wide map of diversity in Plasmodium falciparumNature Genetics, 2006
- A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite ChallengeInfection and Immunity, 2006
- Enhancement of functional antibody responses to AMA1-C1/Alhydrogel®, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotideVaccine, 2006
- Plasmodium falciparum Serine Repeat Protein, a New Target of Monocyte-Dependent Antibody-Mediated Parasite KillingInfection and Immunity, 2002
- Genome sequence of the human malaria parasite Plasmodium falciparumNature, 2002
- Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human AntibodiesThe Journal of Experimental Medicine, 1997
- Immunity to Malaria and Naturally Acquired Antibodies to the Circumsporozoite Protein ofPlasmodium falciparumNew England Journal of Medicine, 1986